Qiming Venture Partners Overview
- Investor Type
- Venture Capital
- Status
- Active
- Professionals
- 35
- Investments
- 651
- Portfolio
- 276
- Exits
- 124
Qiming Venture Partners General Information
Description
Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Shenzhen, Hong Kong, Seattle, Boston, and San Francisco Bay Area. Currently, the firm manages nine US Dollar funds and five RMB funds with $5.3 billion assets under management. Since establishment, the firm has invested in outstanding companies in the TMT and healthcare industries at the early and growth stages. Since its debut, the firm has backed over 350 fast-growing and innovative companies.
Contact Information
Website
Year Founded
2006
Investor Status
Actively Seeking New Investments
Primary Investor Type
Venture Capital
Primary Office
- Room 3906 Jinmao Tower
- 88 Century Boulevard
- Shanghai, 200121
- China
+86 021 0000 0000
Qiming Venture Partners Investments (651)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
|---|---|---|---|---|---|---|
| Nice Tuan | 30-Nov-2020 | Later Stage VC | 00000 | Internet Retail | Generating Revenue | |
| 0000000000 0000000 | 23-Nov-2020 | 00000 00000 | 000.00 | Medical Supplies | Generating Revenue | |
| 00000000 | 21-Nov-2020 | 00000 00000 | 000.00 | Computers, Parts and Peripherals | Generating Revenue | |
| 000000000 00000000 | 18-Nov-2020 | 00000 00000 | 0000 | Drug Discovery | Startup | 00000 00000 00.0 |
| 00000 000000000 | 18-Nov-2020 | 00000 00000 | 0000 | Biotechnology | Pre-Clinical Trials | 0000 000000 |
| 0000 000000 | 16-Nov-2020 | 00000 00000 | Drug Discovery | Generating Revenue | ||
| 0000 0000000000 (0 | 02-Nov-2020 | 00000 00000 | 0000 | Communication Software | Profitable | |
| 0000000 0000000000 | 19-Oct-2020 | 00000 00000 | 00000 | Drug Discovery | Generating Revenue | |
| Cool College | 19-Oct-2020 | Early Stage VC | 000.00 | Education and Training Services (B2B) | Generating Revenue | |
| Talaris Therapeutics | 30-Sep-2020 | Later Stage VC | 00000 | Drug Delivery | Clinical Trials - Phase 3 | 0000 000000 |
Qiming Venture Partners Exits (122)
| Company Name | Exit Date | Exit Type | Exit Size |
|---|---|---|---|
| Keysino | 16-Oct-2020 | IPO | 000.00 |
| 00000 000000000 | 07-Oct-2020 | 000 | |
| 00 00000 | 30-Sep-2020 | 000 00 00000000 | |
| 0000000000 | 30-Sep-2020 | 000000000 00000000 | 000.00 |
| 000 000 | 28-Sep-2020 | 000000 0000000000 | 00000 |
| 00000000 000000 00 | 11-Sep-2020 | 000000000 00000000 | 00.00 |
| 0000000 000000000 | 01-Sep-2020 | 000000000 00000000 | 000.00 |
| 0000ö000000 | 01-Sep-2020 | 000000000 00000000 | 000 |
| Transwarp (Big Data) | 28-Aug-2020 | Secondary Transaction - Private | 00.000 |
| CoolMath (China) | 21-Aug-2020 | Merger/Acquisition |
Qiming Venture Partners Investments by Industry, Year, and Region
Investments by Industry
Investments by Year
Investments by Region
PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.
Request a free trialQiming Venture Partners Team (69)
| Name | Title | Deals | Funds | Boards | Office |
|---|---|---|---|---|---|
| Grace Lee | Partner, Group Chief Operating Officer & Chief Financial Officer | 0 | Hong Kong, Hong Kong | ||
| Gary Rieschel | Co-Founding Managing Partner | 00 | 00 | 0 | Shanghai, China |
| Christopher Shen MD | Managing Partner | 0 | 0 | 0 | Beijing, China |
| Nisa Leung | Managing Partner | 00 | 00 | 00 | Hong Kong, Hong Kong |
| Xubo Hu | Managing Partner | 000 | 00 | 00 | Shanghai, China |
Qiming Venture Partners Co-Investors (559)
| Name | With | Exits | Lead Partner | Series | Industry |
|---|---|---|---|---|---|
| Sequoia Capital China | 16 | 0 | 00 |
|
|
| GGV Capital | 00 | 0 | 0 |
|
|
| IDG Capital | 00 | 0 | 0 |
|
|
| Legend Capital | 00 | 0 | 0 |
|
|
| Lilly Asia Ventures | 00 | 0 | 0 |
|
|